C12Y 304/21075
Furin
Official title: Furin (3.4.21.75)
C12Y304/21075 (Furin) appears on 19 US grants and 37 published applications in this corpus.
Search patents in C12Y- Granted patents
- 19
- Published applications
- 37
- Assignees
- 31
- Inventors
- 145
- Latest grant
- 26 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 2 |
| 2015 | 2 | 3 |
| 2016 | 1 | 2 |
| 2017 | 2 | 1 |
| 2018 | 1 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 3 |
| 2021 | 2 | 3 |
| 2022 | 1 | 2 |
| 2023 | 0 | 6 |
| 2024 | 3 | 2 |
| 2025 | 2 | 4 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for immunomodulation26 Aug 2025US 12,397,037 B2Children's Medical Center Corporation
- Modified activin A6 May 2025US 12,291,554 B2Mitsubishi Chemical Corporation
- Complement factor I-related compositions and methods15 Oct 2024US 12,116,606 B2Vertex Pharmaceuticals Incorporated
- Oligonucleotides for SARS-CoV-2 modulation3 Sep 2024US 12,077,758 B2University of Massachusetts
- Multiple transgene recombinant adenovirus16 Jul 2024US 12,036,247 B2EpicentRx, Inc.
- Furin sensors and applications thereof7 May 2026US 2026/0125736 A1Flareon Biotech GmbH
- Methods and compositions for immunomodulation18 Dec 2025US 2025/0381244 A1Children's Medical Center Corporation
- Complement factor i-related compositions and methods1 May 2025US 2025/0136965 A1Vertex Pharmaceuticals Incorporated
- Furin-cleavable delivery constructs27 Mar 2025US 2025/0099599 A1Thornhill Therapeutics, Inc.
- Methods for treatment response to cancers2 Jan 2025US 2025/0003010 A1Gradalis, Inc.
Most cited
By later US patents
- Process for the preparation of molecularly imprinted polymers useful for separation of enzymes16US 6,379,599 B1Council of Scientific and Industrial Research · 2002
- Furin polypeptides with improved characteristics11US 6,596,526 B1Baxter Aktiengesellschaft · 2003
- Aerosol delivery systems, compositions and methods11US 8,945,605 B2Parion Sciences, Inc. · 2015
- Producing recombinant SARS-CoV-2 spike protein in a pre-fusion state10US 11,020,474 B12021
- Humanized monoclonal antibodies against the extracellular domain of human death receptor 51US 9,725,517 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences · 2017